Metropolitan Life Insurance Company (MetLife)’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-78	Closed	-$17.5K	–	2374
2022 Q3	$17.5K	Hold	78	–	–	﹤0.01%	2087
2022 Q2	$14.7K	Hold	78	–	–	﹤0.01%	2195
2022 Q1	$19.3K	Buy	+78	New	+$12.3K	﹤0.01%	2113
2021 Q1	–	Sell	-278	Closed	-$102K	–	2603
2020 Q4	$102K	Hold	278	–	–	﹤0.01%	2354
2020 Q3	$67.8K	Hold	278	–	–	﹤0.01%	2416
2020 Q2	$79.9K	Buy	+278	New	+$81.9K	﹤0.01%	2382
2020 Q1	–	Sell	-269	Closed	-$120K	–	2556
2019 Q4	$120K	Sell	269 -36	-12%	-$12.8K	﹤0.01%	2223
2019 Q3	$93.7K	Buy	305 +239	+362%	+$77.6K	﹤0.01%	2336
2019 Q2	$21.1K	Buy	+66	New	+$22.9K	﹤0.01%	2602

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s EIGR Position: Q4 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 78 shares — an estimated $17.5K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in EIGR in Q2 2019 and held it in 9 quarters. The position peaked at $120K in Q4 2019. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

Metropolitan Life Insurance Company (MetLife) reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 78 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $17.5K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2019 and held it in 9 quarters.
Metropolitan Life Insurance Company (MetLife)'s Eiger BioPharmaceuticals, Inc. position peaked at $120K in Q4 2019.
81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2022, filed 15 Feb 2023.